These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 29584548)

  • 1. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
    Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
    J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
    Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
    Haukaas FS; Ohna A; Krivasi T
    Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
    Pott C; Sehn LH; Belada D; Gribben J; Hoster E; Kahl B; Kehden B; Nicolas-Virelizier E; Spielewoy N; Fingerle-Rowson G; Harbron C; Mundt K; Wassner-Fritsch E; Cheson BD
    Leukemia; 2020 Feb; 34(2):522-532. PubMed ID: 31462735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    Rummel MJ; Janssens A; MacDonald D; Keating MM; Zaucha JM; Davis J; Lasher J; Babanrao Pisal C; Izquierdo M; Friedberg JW
    Br J Haematol; 2021 Jun; 193(6):1123-1133. PubMed ID: 33973233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
    Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
    Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
    Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
    Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
    Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
    N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
    Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
    Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Rafia R; Pandor A; Davis S; Stevens JW; Harnan S; Clowes M; Sorour Y; Cutting R
    Pharmacoeconomics; 2018 Oct; 36(10):1143-1151. PubMed ID: 29594951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
    Guzauskas GF; Masaquel A; Thuresson PO; Dawson K; Veenstra DL
    Leuk Lymphoma; 2019 Jul; 60(7):1668-1676. PubMed ID: 30632837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.